Carvedilol ameliorates low-turnover bone disease in non-obese type 2 diabetes.
about
Carvedilol decrease IL-1β and TNF-α, inhibits MMP-2, MMP-9, COX-2, and RANKL expression, and up-regulates OPG in a rat model of periodontitisThe spontaneously diabetic torii rat: an animal model of nonobese type 2 diabetes with severe diabetic complications.A review of rodent models of type 2 diabetic skeletal fragility.Anti-oxidative Effect of the β-blocker Carvedilol on Diabetic Nephropathy in Non-obese Type 2 Diabetic Rats.
P2860
Carvedilol ameliorates low-turnover bone disease in non-obese type 2 diabetes.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Carvedilol ameliorates low-turnover bone disease in non-obese type 2 diabetes.
@en
Carvedilol ameliorates low-turnover bone disease in non-obese type 2 diabetes.
@nl
type
label
Carvedilol ameliorates low-turnover bone disease in non-obese type 2 diabetes.
@en
Carvedilol ameliorates low-turnover bone disease in non-obese type 2 diabetes.
@nl
prefLabel
Carvedilol ameliorates low-turnover bone disease in non-obese type 2 diabetes.
@en
Carvedilol ameliorates low-turnover bone disease in non-obese type 2 diabetes.
@nl
P2093
P2860
P356
P1476
Carvedilol ameliorates low-turnover bone disease in non-obese type 2 diabetes
@en
P2093
Hideki Fujii
Hideyuki Yamato
Keiji Kono
Masami Shinohara
Riko Kitazawa
Shinichi Nishi
Shunsuke Goto
Sohei Kitazawa
Yasuhiro Hamada
P2860
P304
P356
10.1159/000330853
P577
2011-08-09T00:00:00Z